Pharma News, 2019

(Reuters) - The U.

AstraZeneca and Daiichi Sankyo have presented new mid-stage data showing “clinically meaningful” responses in patients with advanced breast cancer taking trastuzumab deruxtecan.

2019 has seen a boom in the use of cutting edge robotic technology and there is more to come.

The Food and Drug Administration reversed its decision on a treatment for Duchenne muscular dystrophy from Sarepta Therapeutics (SRPT), approving a previously rejected drug without explaining ...

Dr.

The U.

Amneal Pharmaceuticals has signed an agreement to acquire a majority stake in generic pharmaceuticals provider AvKARE for an implied enterprise value of $340m.

Dermira has secured fast track designation from the US Food and Drug Administration (FDA) for lebrikizumab for the treatment of moderate-to-severe atopic dermatitis.

Bayer’s eager to send its animal health unit to Elanco so it can focus its healthcare efforts on pharmaceuticals.

Sanofi’s new CEO Paul Hudson turned heads earlier this week with his bold prediction that Dupixent, the company’s eczema drug that’s partnered with Regeneron, would peak at €10 billion ($1...

(Reuters) - An experimental cancer drug developed by AstraZeneca and Daiichi Sankyo kept metastatic breast cancer at bay for months in women who had exhausted other treatment options, its firs...

(Reuters) - A print advertisement of Alkermes Plc's addiction treatment, Vivitrol, is false or misleading as it omits important risk information associated with its use, the Food and Drug ...